BIOLASE Inc.Find Ratings Reports
BIOLASE INC's gross profit margin for the fourth quarter of its fiscal year 2017 has decreased when compared to the same period a year ago. Even though sales decreased, the net income has increased. BIOLASE INC has strong liquidity. Currently, the Quick Ratio is 1.65 which shows the ability to cover short-term cash needs. The company's liquidity has increased from the same period last year.
At the same time, stockholders' equity ("net worth") has greatly increased by 32.60% from the same quarter last year. The key liquidity measurements indicate that the company is unlikely to face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q4 FY17||Q4 FY16|
|Net Sales ($mil)||12.63||13.76|
|Net Income ($mil)||-3.84||-4.43|
|Balance Sheet||Q4 FY17||Q4 FY16|
|Cash & Equiv. ($mil)||11.9||9.18|
|Total Assets ($mil)||42.98||41.94|
|Total Debt ($mil)||0.0||0.16|
|Profitability||Q4 FY17||Q4 FY16|
|Gross Profit Margin||31.11||41.24|
|Return on Assets||-39.2||-36.64|
|Return on Equity||-71.18||-79.56|
|Debt||Q4 FY17||Q4 FY16|
|Share Data||Q4 FY17||Q4 FY16|
|Shares outstanding (mil)||102.34||67.57|
|Div / share||0.0||0.0|
|Book value / share||0.29||0.33|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||116348.0||349307.0|
SELL. This stock’s P/E ratio is negative, making its value useless in the assessment of premium or discount valuation, only displaying that the company has negative earnings per share. For additional comparison, its price-to-book ratio of 1.12 indicates a significant discount versus the S&P 500 average of 3.22 and a significant discount versus the industry average of 5.90. The price-to-sales ratio is well below both the S&P 500 average and the industry average, indicating a discount. After reviewing these and other key valuation criteria, BIOLASE INC proves to trade at a discount to investment alternatives within the industry.
|BIOL NM||Peers 116.85||BIOL NM||Peers 33.72|
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.
BIOL's P/E is negative making this valuation measure meaningless.
Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
BIOL's P/CF is negative making the measure meaningless.
|BIOL NM||Peers 39.88||BIOL NA||Peers 1.22|
Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.
BIOL's ratio is negative making this valuation measure meaningless.
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
Ratio not available.
|BIOL 1.12||Peers 5.90||BIOL 0.00||Peers -21.80|
Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
BIOL is trading at a significant discount to its peers.
Neutral. Higher earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
The growth rate for BIOL is not available.
|BIOL 0.70||Peers 6.08||BIOL -9.43||Peers 15.12|
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
BIOL is trading at a significant discount to its industry on this measurement.
Lower. A sales growth rate that trails the industry implies that a company is losing market share.
BIOL significantly trails its peers on the basis of sales growth